Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32525715.
- Also identified by DOI 10.7326/M20-2933 and PMC identifier 7322770.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this commentary, the authors explain and call for a broader use of outcome-adaptive randomization when designing clinical trials to test multiple COVID-19 interventions. This design potentially reduces the number of deaths or other adverse outcomes incurred during a trial.
Medical subject headings
- Coronavirus Infections
- Pneumonia, Viral
- Randomized Controlled Trials as Topic
- Research Design